|
|
Volumn 381, Issue 2, 2019, Pages 106-108
|
|
Reforming the orphan drug act for the 21st Century
a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIFAMPRIDINE;
DABRAFENIB;
GENERIC DRUG;
IVACAFTOR PLUS LUMACAFTOR;
NUSINERSEN;
ONASEMNOGENE ABEPARVOVEC;
ORPHAN DRUG;
PIRFENIDONE;
ZOLGENSMA;
COST BENEFIT ANALYSIS;
CYSTIC FIBROSIS;
DISEASE SEVERITY;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
EATON LAMBERT SYNDROME;
FIBROSING ALVEOLITIS;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE ACCESS;
HEALTH CARE POLICY;
HEALTH PROGRAM;
HUMAN;
METASTATIC MELANOMA;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
RARE DISEASE;
REVIEW;
SPINAL MUSCULAR ATROPHY;
UNITED KINGDOM;
UNITED STATES;
DRUG DEVELOPMENT;
DRUG MANUFACTURE;
ECONOMICS;
FINANCIAL MANAGEMENT;
LEGISLATION AND JURISPRUDENCE;
PATENT;
DRUG COSTS;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
DRUGS, GENERIC;
HEALTH CARE REFORM;
HUMANS;
ORPHAN DRUG PRODUCTION;
PATENTS AS TOPIC;
RARE DISEASES;
RESEARCH SUPPORT AS TOPIC;
UNITED STATES;
|
|
EID: 85068824905
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1902943 Document Type: Review |
|
Times cited : (27)
|
|
References (5)
|
